AllSci News
Eli Lilly adds preclinical Alzheimer's candidate through USD 1b deal with AlzeCure
Eli Lilly has agreed to license global rights to Alzstatin ACD680, a preclinical small-molecule gamma-secretase modulator for Alzheimer's disease, from...
Cartesian Therapeutics licenses mRNA CAR-T technology to WestGene Biopharma for autoimmune diseases
Cartesian Therapeutics (Nasdaq: RNAC) has licensed its mRNA payload technology to China-based WestGene Biopharma in a deal that pairs Cartesian's clinically...
J&J bags Firefly Bio's degrader antibody conjugate platform for USD 1b
Johnson & Johnson (NYSE: JNJ) has agreed to acquire Firefly Bio, Inc. for USD 1 billion in cash, adding the company's proprietary Firelink™ degrader...
Pfizer/Zai Lab’s Tivdak wins first China market nod for cervical cancer
China’s NMPA issued an approval for Tivdak (tisotumab vedotin) as a treatment for recurrent or metastatic cervical cancer, making it the first…
Bial ends development of GCase activator pariceract in Parkinson's after Phase II fail
Portugal-based Bial reported that pariceract (BIA 28-6156; formerly LTI-291, LTI-00291), its oral small-molecule allosteric activator of...
Chugai's ALK-targeting AQUA07 enters Phase I for ALK-positive NSCLC, combined with lorlatinib
Chugai enters first-in-human territory with AQUA07 in ALK-positive NSCLC, pairing novel oral agent with lorlatinib
Alnylam puts siRNA with undisclosed-target into Phase I for obesity management
Alnylam Pharmaceuticals (Nasdaq: ALNY) has initiated a first-in-human Phase I trial of ALN-6222, an investigational siRNA therapeutic administered...
BeOne/Huahui Health's trispecific antibody targeting PD-1, CTLA-4, and VEGF-A enters the clinic
Beijing-based Huahui Health has initiated a first-in-human trial of HH160, a potential first-in-class trispecific antibody engineered to block PD-1, CTLA-4,...
Gilead and Merck to seek approval for HIV combo after positive Phase III
Gilead Sciences (Nasdaq: GILD) and Merck (NYSE: MRK) reported that the investigational islatravir lenacapavir HIV treatment met its primary efficacy...
FDA nods label expansion for Pfizer’s Hympavzi to pediatric use
The US FDA approved an expanded indication for Hympavzi (marstacimab-hncq), Pfizer’s (NYSE: PFE) anti-tissue factor pathway inhibitor antibody, extending its use to…
Soligenix seeks CEPI backing for Ebola vaccine development
Princeton, New Jersey-based Soligenix, Inc. (Nasdaq: SNGX) has announced that it is applying to the Coalition for Epidemic Preparedness Innovations (CEPI)...
GSK makes USD 10.6b move for Nuvalent to enter lung cancer with ROS1 and ALK inhibitors
GSK has agreed to acquire Nuvalent, Inc. (Nasdaq: NUVL) for USD 10.6 billion, gaining two late-stage kinase inhibitors — zidesamtinib (NVL-520) and...
Merck, Gilead rein in ambitions for Trodelvy in lung cancer after Phase III stumble
Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the discontinuation of the Phase III KEYNOTE-D46/EVOKE-03 study after sacituzumab govitecan —...
Innovent's IBI3031 bispecific IGF-1R/TSHR antibody enters Phase I for thyroid eye disease
Innovent Moves IBI3031 into First-in-Human Testing with a Bispecific Strategy for Thyroid Eye Disease
ADA: Eli Lilly shows off triple-G agonist retatrutide's strength in obesity
Eli Lilly and Company (NYSE: LLY) reported pivotal Phase III data for retatrutide, its investigational GIP, GLP-1, and glucagon triple hormone receptor...
The AllSci Brief
Systematic R&D and deal news. Daily.